AU2010269962B2 - Methods and compositions for use in cellular therapies - Google Patents

Methods and compositions for use in cellular therapies Download PDF

Info

Publication number
AU2010269962B2
AU2010269962B2 AU2010269962A AU2010269962A AU2010269962B2 AU 2010269962 B2 AU2010269962 B2 AU 2010269962B2 AU 2010269962 A AU2010269962 A AU 2010269962A AU 2010269962 A AU2010269962 A AU 2010269962A AU 2010269962 B2 AU2010269962 B2 AU 2010269962B2
Authority
AU
Australia
Prior art keywords
cells
stem cells
mesenchymal stem
inflammatory
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010269962A
Other languages
English (en)
Other versions
AU2010269962A1 (en
Inventor
Dirk Buscher
Eleuterio Lombardo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2010269962A1 publication Critical patent/AU2010269962A1/en
Assigned to TIGENIX, S.A. reassignment TIGENIX, S.A. Alteration of Name(s) of Applicant(s) under S113 Assignors: CELLERIX SA
Application granted granted Critical
Publication of AU2010269962B2 publication Critical patent/AU2010269962B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: TIGENIX, S.A.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
AU2010269962A 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies Active AU2010269962B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22427509P 2009-07-09 2009-07-09
US61/224,275 2009-07-09
PCT/IB2010/001968 WO2011004264A1 (en) 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies

Publications (2)

Publication Number Publication Date
AU2010269962A1 AU2010269962A1 (en) 2012-03-01
AU2010269962B2 true AU2010269962B2 (en) 2016-04-14

Family

ID=42782196

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010269962A Active AU2010269962B2 (en) 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies

Country Status (19)

Country Link
US (1) US8679834B2 (https=)
EP (2) EP3150703A1 (https=)
JP (1) JP5892931B2 (https=)
KR (1) KR101788885B1 (https=)
CN (2) CN107007626A (https=)
AU (1) AU2010269962B2 (https=)
BR (1) BR112012000534A2 (https=)
CA (1) CA2767300C (https=)
DK (1) DK2451943T3 (https=)
ES (1) ES2479542T3 (https=)
HU (1) HUE031921T2 (https=)
IL (1) IL217377A (https=)
MX (1) MX359639B (https=)
NZ (1) NZ597975A (https=)
PL (1) PL2451943T3 (https=)
PT (1) PT2451943T (https=)
RU (1) RU2610427C2 (https=)
SG (2) SG177582A1 (https=)
WO (1) WO2011004264A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
KR101536239B1 (ko) 2005-09-23 2015-07-13 셀레릭스, 에스.엘. 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도
WO2011006029A1 (en) 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
US11090363B2 (en) 2009-07-10 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Vasoactive intestinal peptide release from microparticles
US20140154274A1 (en) * 2011-01-12 2014-06-05 Tigenix Nv Methods and compositions for use in intralymphatic cellular therapies
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
WO2013149211A2 (en) * 2012-03-30 2013-10-03 University Of Southern California Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US10258652B2 (en) 2014-12-18 2019-04-16 Pluristem Ltd. Methods and compositions for treating and preventing muscle wasting disorders
WO2016107563A1 (zh) * 2014-12-29 2016-07-07 西比曼生物科技（上海）有限公司 一种用于治疗上呼吸道疾病的脂肪间充质祖细胞复合物
US20180015125A1 (en) 2015-03-23 2018-01-18 Pluristem Ltd. Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof
AU2017220148A1 (en) 2016-02-18 2018-07-19 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
EP3624815A4 (en) 2017-05-15 2021-01-20 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS
EP3624816A4 (en) 2017-05-15 2021-02-24 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH STEM CELLS DERIVED FROM ADIPOUS TISSUE
CN107281469A (zh) * 2017-07-17 2017-10-24 广东颜值科技有限公司 一种细胞组合物及其制备方法和应用
CN107349419A (zh) * 2017-07-17 2017-11-17 广东颜值科技有限公司 一种细胞组合物及其制备方法和应用
CN112912087A (zh) * 2018-09-14 2021-06-04 卢卡科学株式会社 线粒体向淋巴器官中的移植以及用于该移植的组合物
AU2020240049A1 (en) * 2019-03-19 2021-11-04 Figene, Llc Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof
AU2020284114B2 (en) * 2019-05-31 2025-06-26 Fibrobiologics, Inc. Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
US20240000850A1 (en) * 2020-04-08 2024-01-04 Figene, Llc Methods and compositions for allergy and asthma treatment using fibroblasts

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015929A2 (en) * 2008-08-04 2010-02-11 Cellerix Sa Uses of mesenchymal stem cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334474D1 (de) * 2002-07-12 2010-11-18 Univ Johns Hopkins Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
KR101536239B1 (ko) 2005-09-23 2015-07-13 셀레릭스, 에스.엘. 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도
US8241621B2 (en) * 2006-12-18 2012-08-14 Medistem Laboratories Stem cell mediated treg activation/expansion for therapeutic immune modulation
US20090324609A1 (en) * 2007-08-09 2009-12-31 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
EP2191835A4 (en) * 2007-09-07 2011-12-14 Japan Chem Res THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS
EP2279246A4 (en) * 2008-05-02 2012-03-28 Massachusetts Inst Technology METHOD AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015929A2 (en) * 2008-08-04 2010-02-11 Cellerix Sa Uses of mesenchymal stem cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
de Vries IJ et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005 Nov;23(11):1407-13. Epub 2005 Oct 30 *
Figdor CG et al. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004 May;10(5):475-80. Review. *
Gerdoni E et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol. 2007 Mar;61(3):219-27 *
Gonzalez MA et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009 Mar;136(3):978-89. Epub 2008 Nov 27. *
Gonzalez MA et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 2009 Apr;60(4):1006-19 *
Karussis D et al. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs). J Neurol Sci. 2008 Feb 15;265(1-2):131-5. Epub 2007 Jul 3. Review *
Zappia E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005 Sep 1;106(5):1755-61. Epub 2005 May 19. *

Also Published As

Publication number Publication date
PT2451943T (pt) 2017-01-20
EP2451943A1 (en) 2012-05-16
WO2011004264A1 (en) 2011-01-13
CN107007626A (zh) 2017-08-04
IL217377A0 (en) 2012-02-29
AU2010269962A1 (en) 2012-03-01
DK2451943T3 (en) 2017-02-06
SG177582A1 (en) 2012-03-29
MX359639B (es) 2018-10-04
PL2451943T3 (pl) 2017-04-28
CA2767300C (en) 2020-01-07
EP2451943B1 (en) 2016-11-23
SG10201403758SA (en) 2014-10-30
ES2479542T3 (es) 2017-05-26
RU2610427C2 (ru) 2017-02-10
IL217377A (en) 2017-10-31
CN102549147A (zh) 2012-07-04
KR101788885B1 (ko) 2017-10-20
RU2012104529A (ru) 2013-08-20
US20120308585A1 (en) 2012-12-06
BR112012000534A2 (pt) 2017-06-13
ES2479542T1 (es) 2014-08-20
US8679834B2 (en) 2014-03-25
KR20120051006A (ko) 2012-05-21
JP5892931B2 (ja) 2016-03-23
JP2012532859A (ja) 2012-12-20
HUE031921T2 (en) 2017-08-28
NZ597975A (en) 2014-06-27
CA2767300A1 (en) 2011-01-13
MX2012000396A (es) 2012-07-17
EP3150703A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
AU2010269962B2 (en) Methods and compositions for use in cellular therapies
US12186344B2 (en) Cell populations having immunoregulatory activity, method for isolation and uses
US20140154274A1 (en) Methods and compositions for use in intralymphatic cellular therapies
HK1173177B (en) Methods and compositions for use in cellular therapies
HK1173177A (en) Methods and compositions for use in cellular therapies
AU2018253517B2 (en) Cell populations having immunoregulatory activity, method for isolation and uses
AU2012268272A1 (en) Cell populations having immunoregulatory activity, method for isolation and uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): TIGENIX, S.A.